NCT04447651View on ClinicalTrials.gov

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

Active, not recruitingOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

May 15, 2023

Study Completion Date

August 31, 2026

Conditions
Metastatic Solid TumorSF3B1 Gene MutationSpliceosome MutationU2AF1 Gene MutationSRSF2 Gene Mutation
Interventions
OTHER

Recommendation for treatment with immunotherapy

Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.

Trial Locations (1)

21236

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Vanderbilt University

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Avon Breast Health Access Fund

UNKNOWN

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT04447651 - Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | Biotech Hunter | Biotech Hunter